ArticleThoracic cancer2026
Copy Number Amplification and c-Myc Transcriptional Activation-Mediated RNA-Binding Protein MEX3A Promotes EGFR-TKI Resistance in Non-Small-Cell Lung Cancer.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo investigate the functional role and activation mechanisms of RNA-binding protein MEX3A in acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC).
methodsPaired tumor specimens were from 18 advanced NSCLC patients with sensitizing EGFR mutations before treatment and after developing TKI resistance. In vitro functional assays, including CCK-8 and colony formation, were conducted to evaluate the impact of MEX3A on EGFR-TKI sensitivity. At the genomic level, copy number variation (CNV) analysis and quantitative real-time PCR (qRT-PCR) validated the genomic relationship between MEX3A copy number and expression. Transcriptional regulation by c-Myc was examined via qRT-PCR, Western blotting, and chromatin immunoprecipitation (ChIP). Finally, the in vivo effects of MEX3A knockdown on tumor growth and TKI sensitivity were evaluated using a xenograft tumor model.
resultsMEX3A was significantly upregulated in TKI-resistant tissues, correlating with poorer survival. MEX3A promoted EGFR-TKI resistance of NSCLC, both in vitro and in vivo. Mechanistically, at the genomic level, copy number amplification can drive the activation of MEX3A, and at the transcriptional level, the transcription factor c-Myc can activate its expression.
conclusionMEX3A is a key molecule that promotes acquired EGFR-TKI resistance in NSCLC. Its activation is mediated by both genomic copy number amplification and c-Myc-dependent transcriptional regulation, thereby clarifying the activation reasons of MEX3A in TKI resistance at two levels. Our findings suggest that MEX3A may serve as a potential therapeutic target for overcoming TKI resistance in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.